Literature DB >> 8381381

Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey.

L Serfaty1, P Giral, M H Elghouzzi, A M Jullien, R Poupon.   

Abstract

Studies of blood donors positive for antibody to hepatitis C virus on enzyme-linked immunosorbent assay are probably biased by the large number of false-positive results. We evaluated the epidemiological and biological characteristics of 177 such donors with regard to the confirmatory second-generation RIBA test (Ortho Diagnostic Systems) and have compared the results to those from an age- and sex-matched control group of 177 donors negative for antibody to hepatitis C virus on enzyme-linked immunosorbent assay. Second-generation recombinant immunoblot assay was positive in 38% of cases, indeterminate in 6% and negative in 56%. The case-control study showed a significantly higher frequency of intravenous drug abuse (27% vs. 0%), blood transfusion (22% vs. 9%), history of jaundice (21% vs. 7%), elevated ALT level (49% vs. 4%) and HBc antibody positivity (32% vs. 7%) in second-generation recombinant immunoblot assay-positive donors. No such differences were found between the second-generation recombinant immunoblot assay-negative donors and their controls. The 35 second-generation recombinant immunoblot assay-positive donors without histories of transfusion or intravenous drug abuse had a significantly higher frequency of surgery with major blood loss or prolonged stays in areas of hepatitis B virus endemicity than did their controls (20% vs. 0% and 49% vs. 26%, respectively). In conclusion, at least one risk factor for HCV infection was identified in 82% of the second-generation recombinant immunoblot assay-positive donors, 91% of whom could have been identified on the basis of these risk factors, ALT level and presence of HBc antibody.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8381381

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  7 in total

1.  Hepatitis C in asymptomatic British blood donors with indeterminate seropositivity.

Authors:  D J Mutimer; R F Harrison; K B O'Donnell; J Shaw; B A Martin; H Atrah; F A Ala; S Skidmore; S G Hubscher; J M Neuberger
Journal:  BMJ       Date:  1994-10-01

2.  Epidemiology, serological markers, and hepatic disease of anti-HCV ELISA-2-positive blood donors.

Authors:  F J Salmerón; A Palacios; M Pérez-Ruiz; C Torres; S Oyonarte; A Fernández-Montoya; A Ruiz-Extremera
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

3.  Risk factors for hepatitis C virus infection among blood donors in an HIV-epidemic area in Thailand.

Authors:  P Sawanpanyalert; S Boonmar; T Maeda; Y Matsuura; T Miyamura
Journal:  J Epidemiol Community Health       Date:  1996-04       Impact factor: 3.710

4.  Prevalence of anti-HCV and risk factors for hepatitis C virus infection in healthy pregnant women.

Authors:  F Marranconi; P Fabris; C Stecca; L Zampieri; M C Bettini; N Di Fabrizio; F de Lalla
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

5.  Risk factors for hepatitis C virus infection among blood donors in southern Brazil: a case-control study.

Authors:  Ajacio B M Brandão; Sandra Costa Fuchs
Journal:  BMC Gastroenterol       Date:  2002-08-08       Impact factor: 3.067

6.  Is having sex with other men a risk factor for transfusion-transmissible infections in male blood donors in Western countries? A systematic review.

Authors:  Emmy De Buck; Tessa Dieltjens; Veerle Compernolle; Philippe Vandekerckhove
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

7.  Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar.

Authors:  Charles E Ramarokoto; Fanjasoa Rakotomanana; Maherisoa Ratsitorahina; Vaomalala Raharimanga; Richter Razafindratsimandresy; Rindra Randremanana; Mala Rakoto-Andrianarivelo; Dominique Rousset; Voahangy Andrianaja; Vincent Richard; Jean-Louis Soares; Leon P Rabarijaona
Journal:  BMC Infect Dis       Date:  2008-02-29       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.